Skip to NavigationSkip to content

NICE limits access to cancer drugs, study confirms

Published on 10/11/10 at 10:33am

NICE became more restrictive in its assessment of new cancer drugs between 2007 and 2009, a new report suggests.

The review, conducted by Bristol-Myers Squibb, produced its analysis from a list of NICE guidance published between 2007 to the end of 2009 using a health technology resource website.

The research showed that in 2007 one in three new drugs was fully recommended for all eligible patients, but that this dropped to just one in 10 by the end of 2009.

BMS’ associate director health economics Maximilian Lebmeier, who led the analysis, said: “The coalition government has stated their commitment to widening access to medicines and we fully support this. 

“The Cancer Drugs Fund is a good interim initiative for cancer patients, but we would like to see wider reform of the HTA system to make it fairer for all patients and widen access to effective medicines.”

Ben Adams

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches